Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6601 to 6615 of 8896 results

  1. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued Reference number: GID-TA10958

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued Reference number: GID-TA11204

    Technology appraisal guidance
    Discontinued

  3. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development Reference number: GID-TA10843 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  5. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued Reference number: GID-TA10861

    Technology appraisal guidance
    Discontinued

  6. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development Reference number: GID-TA11165 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]

    Discontinued Reference number: GID-TA10880

    Technology appraisal guidance
    Discontinued

  8. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development Reference number: GID-TA11086 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued Reference number: GID-TA10869

    Technology appraisal guidance
    Discontinued

  10. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    In development Reference number: GID-TA11442 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued Reference number: GID-TA11239

    Technology appraisal guidance
    Discontinued

  13. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued Reference number: GID-TA11240

    Technology appraisal guidance
    Discontinued

  14. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

    Technology appraisal guidance
    Discontinued

  15. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued Reference number: GID-TA11256

    Technology appraisal guidance
    Discontinued